CONMED (CNMD) Heads To Robotic Surgery Meeting As Valuation Debate Stays Front And Center
Event-driven focus on CONMED stock
CONMED (CNMD) has drawn fresh attention after announcing its participation in the Society of Robotic Surgery 2026 Annual Meeting, where new clinical data on its AirSeal Insufflation System will be presented.
The trial results, which are set against Stryker's PneumoClear Insufflator, give investors a concrete event to watch as they assess how CONMED positions its surgical technology portfolio within hospital and surgery center budgets.
See our latest analysis for CONMED.
Recent trading suggests momentum in CONMED stock is picking up, with a 30 day share price return of 33.36% and a 90 day share price return of 13.30%, even though the 1 year total shareholder return has declined 8.83% and the 5 year total shareholder return has declined 66.33%.
If this kind of event driven move has your attention, it can be useful to see what other surgical and robotics focused companies are doing too. You can start with 33 robotics and automation stocks
After a 33% move in 30 days and longer term returns that are still in decline, CONMED’s set of clinical assets and current valuation now sit at a crossroads. Does the risk reward still lean toward buyers?
Most Popular Narrative: 9.7% Overvalued
CONMED last closed at $43.45, while the most followed narrative puts fair value at $39.60, creating a clear gap between price and that modeled estimate.
The analysts have a consensus price target of $39.6 for CONMED based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.5 billion, earnings will come to $187.6 million, and it would be trading on a PE ratio of 7.6x, assuming you use a discount rate of 9.1%.
There is a lot baked into that $39.60 figure. Earnings are modeled to grow much faster than revenue, and margins are expected to shift meaningfully higher. It is worth considering how that combination is meant to support a lower future P/E and still reach this fair value.
Result: Fair Value of $39.60 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors still need to weigh risks around CONMED’s reliance on hospital capital budgets, as well as the potential for ongoing supply chain issues to pressure growth and margins.
Find out about the key risks to this CONMED narrative.
Another view on CONMED’s valuation
While the most followed narrative suggests CONMED is 9.7% overvalued versus a $39.60 fair value, our DCF model points in the opposite direction, with CONMED trading at about a 61.9% discount to an estimated future cash flow value of $114.10. Which set of assumptions feels more realistic to you?
For a closer look at how this cash flow based view is constructed, and what would need to happen for CONMED to move closer to that figure, Look into how the SWS DCF model arrives at its fair value.
Next Steps
With mixed signals on CONMED’s valuation and outlook, it helps to move quickly, review the underlying data yourself, and decide where you stand in this debate. To weigh both sides of the story in one place, start with the 3 key rewards and 3 important warning signs.
Looking for more investment ideas beyond CONMED?
If CONMED has sharpened your focus on where capital goes next, do not stop here. Broaden your watchlist with a few targeted stock idea shortlists.
- Target dependable cash generators by scanning companies with strong cash flows and supportive valuations using the 45 high quality undervalued stocks.
- Strengthen your income stream by focusing on companies offering robust payouts and yields screened through the 9 dividend fortresses.
- Prioritize resilience by filtering for companies with lower risk profiles and sturdier fundamentals using the 80 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com